KA34 / Scripps Research Institute, California Institute for Regenerative Medicine - LARVOL DELTA

A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis (clinicaltrials.gov) - P1; N=60; Completed; Sponsor: Calibr, a division of Scripps Research; Active, not recruiting ➔ Completed

Clinical • Trial completion • CNS Disorders • Immunology • Inflammation • Osteoarthritis • Pain • Rheumatology